Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

Comment by cleareyeon Oct 19, 2021 8:41pm
100 Views
Post# 34025179

RE:Is Antibody Rapid Test Still Eligible for EUA/ UPHN

RE:Is Antibody Rapid Test Still Eligible for EUA/ UPHNHi ResearchGuy,

You must have had your intuitive antenae working earlier this morning/last night because SQD issued news on that very topic this afternoon; what follows is the first few paragraphs:

 

 

SQI Diagnostics adjusts to FDA shift from at-home tests

 

2021-10-19 18:23 ET - News Release

 

Mr. Andrew Morris reports

SQI DIAGNOSTICS INC. RESPONDS TO CHANGE IN FDA PRIORITIES IN EMERGENCY USE AUTHORIZATION

SQI Diagnostics Inc. has responded to a recent shift in U.S. Food and Drug Administration (FDA) priorities around emergency use authorization (EUA).

The FDA has announced that, because the COVID-19 pandemic has moved into a new phase with respect to testing, it is no longer prioritizing the review of at-home testing and home sample collection for COVID-19 antibody tests under EUA.

This shift will deprioritize the review of all these devices already submitted for FDA consideration. However, because SQI had not yet submitted its EUA application, it is now able to move from a patient self-collection model to one in which a trained medical professional will collect a whole blood sample.

"As we have seen throughout the pandemic, changing government and regulatory priorities in the face of new or evolving circumstances is to be expected," said Andrew Morris, president and chief executive officer of SQI Diagnostics. "SQI is in the fortunate position of being able to pivot our ongoing clinical validation study to meet the new priorities of the FDA for EUA review."

<< Previous
Bullboard Posts
Next >>